REFLUDAN [lepirudin (rDNA) for injection]: the first direct thrombin inhibitor FDA-approved for heparin induced thrombocytopenia (HIT)

Learn more about the benefits of REFLUDAN
This section contains REFLUDAN laboratory and clinical efficacy data
This section contains information regarding the safe administration of REFLUDAN for the treatment of heparin induced thrombocytopenia (HIT)
This section describes adverse events reported in REFLUDAN clinical trials
This section contains information regarding the safe administration of REFLUDAN for the treatment of heparin induced thrombocytopenia (HIT)
This section describes the dosage and administration of REFLUDAN in the treatment of heparin induced thrombocytopenia (HIT)
Heparin induced thrombocytopenia
A summary of pivotal trial data for REFLUDAN is covered in this section
This section provides access to a variety of resources to obtain in-depth information on heparin induced thrombocytopenia (HIT) and REFLUDAN
Find out what your peers are saying about heparin induced thrombocytopenia (HIT)...

©2007 Bayer Healthcare Pharmaceuticals Inc. All rights reserved.
H.I.T. BACK with REFLUDAN to protect life and limb
References
1.  REFLUDAN® [lepirudin (rDNA) for injection] Prescribing Information.
2.  Greinacher A, Völpel H, Janssens U, et al, for the HIT Investigators Group. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99:73-80. (HAT-1)
3.  Lubenow N, Eichler P, Greinacher A. Results of a large drug-monitoring program confirm the safety and efficacy of lepirudin in patients with immune-mediated heparin-induced thrombocytopenia (HIT). Presented at The American Society of Hematology 44th Annual Meeting. Philadelphia, Pa, December 6-10, 2002. Abstract.
4.  Data on file, Berlex Laboratories, Inc.
5.  Coumadin® (warfarin sodium) Prescribing Information.


<< Back
Terms of Use      Privacy Policy      About Our New Company
Bayer Healthcare Pharmaceuticals